Brief: Protara Therapeutics Announces Dosing Of First Patients In Phase 1B Advanced-1EXP Trial Of TARA-002
15/05/2023 13:14
May 15 (Reuters) - Protara Therapeutics Inc TARA.O :
* PROTARA THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENTS IN
PHASE
1B ADVANCED-1EXP TRIAL OF TARA-002 IN NMIBC PATIENTS WITH
CARCINOMA IN SITU
* PROTARA THERAPEUTICS - PLANS TO INITIATE ADVANCED-2, A
PHASE
1B/2 OPEN-LABEL TRIAL EVALUATING INTRAVESICAL TARA-002 IN UP TO
102 PATIENTS WITH CIS
* PROTARA THERAPEUTICS INC - ADVANCED-2 IS EXPECTED TO
INITIATE IN
SECOND HALF OF 2023
Source text for Eikon: ID:nGNX2lVD8V
Further company coverage: TARA.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses